Organon & Co.
OGNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframePart of the healthcare sector, Organon & Co. (OGN) is listed under Drug Manufacturers - General. The company carries a $3.51B market cap, placing it firmly in the mid-cap category. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Market Cap
$3.51B
Beta
1.55
P/E (TTM)
14.39
P/E (Fwd)
3.65
EPS (TTM)
$0.93
EPS (Fwd)
$3.66
ROE
34.1%
ROA
5.9%
Cash
$1.12B
Total Debt
$8.57B
Free CF
$529.1M
52W Change
40.4%
Annual Financials
Cash vs Debt
Organon & Co. carries $8.57B in total debt against $1.12B in cash reserves — debt is roughly 7.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $529.1M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 34.1%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.17B (2022) to $6.22B (2025).
A beta of 1.55 means OGN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Organon & Co. and its sector.